141 related articles for article (PubMed ID: 9310138)
1. Expression of globo-series gangliosides in human renal cell carcinoma.
Saito S; Orikasa S; Satoh M; Ohyama C; Ito A; Takahashi T
Jpn J Cancer Res; 1997 Jul; 88(7):652-9. PubMed ID: 9310138
[TBL] [Abstract][Full Text] [Related]
2. Disialosyl galactosylgloboside as an adhesion molecule expressed on renal cell carcinoma and its relationship to metastatic potential.
Satoh M; Handa K; Saito S; Tokuyama S; Ito A; Miyao N; Orikasa S; Hakomori S
Cancer Res; 1996 Apr; 56(8):1932-8. PubMed ID: 8620516
[TBL] [Abstract][Full Text] [Related]
3. Inverse relationship of expression between GM3 and globo-series ganglioside in human renal cell carcinoma.
Saito S; Nojiri H; Satoh M; Ito A; Ohyama C; Orikasa S
Tohoku J Exp Med; 2000 Apr; 190(4):271-8. PubMed ID: 10877509
[TBL] [Abstract][Full Text] [Related]
4. Four new human renal cell carcinoma cell lines expressing globo-series gangliosides.
Satoh M; Nejad FM; Nakano O; Ito A; Kawamura S; Ohyama C; Saito S; Orikasa S
Tohoku J Exp Med; 1999 Oct; 189(2):95-105. PubMed ID: 10775053
[TBL] [Abstract][Full Text] [Related]
5. Monoclonal antibody (5F3) defining renal cell carcinoma-associated antigen disialosyl globopentaosylceramide (V3NeuAcIV6NeuAcGb5), and distribution pattern of the antigen in tumor and normal tissues.
Ito A; Saito S; Masuko T; Oh-Eda M; Matsuura T; Satoh M; Nejad FM; Enomoto T; Orikasa S; Hakomori SI
Glycoconj J; 2001 Jun; 18(6):475-85. PubMed ID: 12084983
[TBL] [Abstract][Full Text] [Related]
6. Clinicopathological significance of ganglioside DSGb5 expression in renal cell carcinoma.
Itoh J; Ito A; Shimada S; Kawasaki Y; Kakoi N; Saito H; Mitsuzuka K; Watanabe M; Satoh M; Saito S; Arai Y
Glycoconj J; 2017 Apr; 34(2):267-273. PubMed ID: 28205070
[TBL] [Abstract][Full Text] [Related]
7. A novel ganglioside isolated from renal cell carcinoma.
Ito A; Levery SB; Saito S; Satoh M; Hakomori S
J Biol Chem; 2001 May; 276(20):16695-703. PubMed ID: 11278988
[TBL] [Abstract][Full Text] [Related]
8. High incidence of GalNAc disialosyl lactotetraosylceramide in metastatic renal cell carcinoma.
Maruyama R; Saito S; Bilim V; Hara N; Itoi T; Yamana K; Nishiyama T; Arai Y; Takahashi K; Tomita Y
Anticancer Res; 2007; 27(6C):4345-50. PubMed ID: 18214042
[TBL] [Abstract][Full Text] [Related]
9. Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: possible role of disialogangliosides in tumor progression.
Ito A; Handa K; Withers DA; Satoh M; Hakomori S
FEBS Lett; 2001 Aug; 504(1-2):82-6. PubMed ID: 11522302
[TBL] [Abstract][Full Text] [Related]
10. mTOR and mTOR phosphorylation status in primary and metastatic renal cell carcinoma tissue: differential expression and clinical relevance.
Rausch S; Schollenberger D; Hennenlotter J; Stühler V; Kruck S; Stenzl A; Bedke J
J Cancer Res Clin Oncol; 2019 Jan; 145(1):153-163. PubMed ID: 30368665
[TBL] [Abstract][Full Text] [Related]
11. Binding specificity of siglec7 to disialogangliosides of renal cell carcinoma: possible role of disialogangliosides in tumor progression.
Ito A; Handa K; Withers DA; Satoh M; Hakomori S
FEBS Lett; 2001 Jun; 498(1):116-20. PubMed ID: 11389909
[TBL] [Abstract][Full Text] [Related]
12. Differential expression of TIM-3 between primary and metastatic sites in renal cell carcinoma.
Zhang X; Yin X; Zhang H; Sun G; Yang Y; Chen J; Shu K; Zhao J; Zhao P; Chen N; Wang J; Shen P; Zeng H
BMC Cancer; 2019 Jan; 19(1):49. PubMed ID: 30630458
[TBL] [Abstract][Full Text] [Related]
13. Enhancer of zeste homolog 2 expression is associated with metastasis and adverse clinical outcome in clear cell renal cell carcinoma: a comparative study and review of the literature.
Xu B; Abourbih S; Sircar K; Kassouf W; Mansure JJ; Aprikian A; Tanguay S; Brimo F
Arch Pathol Lab Med; 2013 Oct; 137(10):1326-36. PubMed ID: 24079759
[TBL] [Abstract][Full Text] [Related]
14. Ganglioside DSGb5, preferred ligand for Siglec-7, inhibits NK cell cytotoxicity against renal cell carcinoma cells.
Kawasaki Y; Ito A; Withers DA; Taima T; Kakoi N; Saito S; Arai Y
Glycobiology; 2010 Nov; 20(11):1373-9. PubMed ID: 20663960
[TBL] [Abstract][Full Text] [Related]
15. Metastatic renal cell carcinoma to the bladder: a clinicopathologic and immunohistochemical study.
Sim SJ; Ro JY; Ordonez NG; Park YW; Kee KH; Ayala AG
Mod Pathol; 1999 Apr; 12(4):351-5. PubMed ID: 10229498
[TBL] [Abstract][Full Text] [Related]
16. Impact of caveolin-1 expression on clinicopathological parameters in renal cell carcinoma.
Horiguchi A; Asano T; Asakuma J; Asano T; Sumitomo M; Hayakawa M
J Urol; 2004 Aug; 172(2):718-22. PubMed ID: 15247769
[TBL] [Abstract][Full Text] [Related]
17. RM2 antigen (beta1,4-GalNAc-disialyl-Lc4) as a new marker for prostate cancer.
Saito S; Egawa S; Endoh M; Ueno S; Ito A; Numahata K; Satoh M; Kuwao S; Baba S; Hakomori S; Arai Y
Int J Cancer; 2005 May; 115(1):105-13. PubMed ID: 15704108
[TBL] [Abstract][Full Text] [Related]
18. "Mucin"-secreting papillary renal cell carcinoma: clinicopathological, immunohistochemical, and molecular genetic analysis of seven cases.
Pivovarcikova K; Peckova K; Martinek P; Montiel DP; Kalusova K; Pitra T; Hora M; Skenderi F; Ulamec M; Daum O; Rotterova P; Ondic O; Dubova M; Curik R; Dunatov A; Svoboda T; Michal M; Hes O
Virchows Arch; 2016 Jul; 469(1):71-80. PubMed ID: 27072821
[TBL] [Abstract][Full Text] [Related]
19. PAX2 and PAX8 expression in primary and metastatic renal tumors: a comprehensive comparison.
Ozcan A; de la Roza G; Ro JY; Shen SS; Truong LD
Arch Pathol Lab Med; 2012 Dec; 136(12):1541-51. PubMed ID: 23194047
[TBL] [Abstract][Full Text] [Related]
20. Costimulatory molecule B7-H1 in primary and metastatic clear cell renal cell carcinoma.
Thompson RH; Gillett MD; Cheville JC; Lohse CM; Dong H; Webster WS; Chen L; Zincke H; Blute ML; Leibovich BC; Kwon ED
Cancer; 2005 Nov; 104(10):2084-91. PubMed ID: 16208700
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
